PHASE-II STUDY OF PROTRACTED INFUSIONAL 5-FLUOROURACIL COMBINED WITH CISPLATINUM FOR ADVANCED GASTRIC-CANCER - REPORT FROM THE JAPAN CLINICAL ONCOLOGY GROUP (JCOG)

Authors
OHTSU A SHIMADA Y YOSHIDA S SAITO H SEKI S MORISE K KURIHARA M
Citation
A. Ohtsu et al., PHASE-II STUDY OF PROTRACTED INFUSIONAL 5-FLUOROURACIL COMBINED WITH CISPLATINUM FOR ADVANCED GASTRIC-CANCER - REPORT FROM THE JAPAN CLINICAL ONCOLOGY GROUP (JCOG), European journal of cancer, 30A(14), 1994, pp. 2091-2093
Citations number
15
Categorie Soggetti
Oncology
Journal title
European journal of cancer → ACNP
ISSN journal
09598049
Volume
30A
Issue
14
Year of publication
1994
Pages
2091 - 2093
Database
ISI
SICI code
0959-8049(1994)30A:14<2091:PSOPI5>2.0.ZU;2-J
Abstract
A phase II study of protracted infusional 5-fluorouracil (5FU) combine d with cisplatin (CDDP) was conducted in patients with advanced gastri c carcinoma. 55 previously untreated patients, including 40 patients w ith measurable disease, were treated with 5FU (800 mg/m(2), days 1-5, protracted infusion) and CDDP (20 mg/m(2), days 1-5, drip infusion). O bjective tumour responses were observed in 17/40 (43%) patients with m easurable disease. Median survival was 7 months. WHO grade 3 or 4 leuc openia occurred in 10/55 patients (18%) and grade 3/4 thrombocytopenia was observed in 4 patients (7%). A randomised trial including this re gimen is now underway in a JCOG study.